WallStSmart

Innodata Inc (INOD)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 3% more annual revenue ($258.90M vs $251.66M). INOD leads profitability with a 12.8% profit margin vs -15.5%. INOD earns a higher WallStSmart Score of 57/100 (C).

INOD

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 8.5Value: 5.7Quality: 8.0
Piotroski: 3/9Altman Z: 4.86

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INOD.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INOD5 strengths · Avg: 9.2/10
Return on EquityProfitability
37.8%10/10

Every $100 of equity generates 38 in profit

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.8610/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.878/10

Growing faster than its price suggests

Revenue GrowthGrowth
22.3%8/10

Revenue surging 22.3% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

INOD4 concerns · Avg: 3.0/10
Price/BookValuation
13.3x4/10

Trading at 13.3x book value

Market CapQuality
$1.30B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
43.4x2/10

Premium valuation, high expectations priced in

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : INOD

The strongest argument for INOD centers on Return on Equity, Debt/Equity, Altman Z-Score. Revenue growth of 22.3% demonstrates continued momentum. PEG of 0.87 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : INOD

The primary concerns for INOD are Price/Book, Market Cap, Piotroski F-Score. A P/E of 43.4x leaves little room for execution misses.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

INOD profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

INOD carries more volatility with a beta of 2.50 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor INFORMATION TECHNOLOGY SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INOD scores higher overall (57/100 vs 41/100) and 22.3% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Innodata Inc

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Innodata Inc. is a global data engineering company in the United States, the United Kingdom, the Netherlands, Canada, and internationally. The company is headquartered in Ridgefield Park, New Jersey.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?